Major Depressive Disorder, Marijuana, and Cannabinoids: Disentangling the Research to Help You Guide Your Patients-View Presentation

Video Transcription

Video Summary

In this webinar, Dr. Edgar Woznika discusses the relationship between major depressive disorder (MDD), marijuana, and cannabinoids. He explains that the endocannabinoid system, which involves the body's own cannabinoids, plays a role in various bodily functions, including mood regulation. He then breaks down the major cannabinoid classes, including THC and CBD, and discusses how they interact with the endocannabinoid system. Dr. Woznika also explains the different forms of cannabis preparation, such as whole cannabis and concentrates, and how their potency has been increasing over time. He emphasizes the addictive potential of highly addictive cannabinoids, such as whole cannabis and THC concentrates, and the need to address cannabis use disorder in patients with MDD. Dr. Woznika examines the evidence for the effects of consumed cannabinoids on mood, including the increased risk of developing MDD and exacerbation of symptoms in patients with MDD. He also briefly touches on state laws regarding cannabis legality. Finally, Dr. Woznika recommends starting a conversation with patients who believe that using THC decreases their symptoms by explaining the difference between acute effects and chronic effects, and discussing the potential risks associated with cannabis use.

Keywords

webinar

Dr. Edgar Woznika

major depressive disorder

marijuana

cannabinoids

endocannabinoid system

THC

CBD

cannabis preparation

potency